questionText: To ask the Secretary of State for Health and Social Care, what assessment has he made of the potential merits of increasing NICE's cost-effectiveness thresholds used to evaluate Highly Specialised Technologies for rare diseases.
answerText: There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard National Institute for Health and Care Excellenc...
heading: Rare Diseases: Medical Treatments